Is there an FDA-approved generic Ozempic or Wegovy right now?

No. As of September 2026, the FDA has not approved and no company sells a generic semaglutide injection or pill in the US. Any product sold as generic Ozempic or Wegovy in the US today is compounded, counterfeit, or unapproved.

Why can Canadians buy generic semaglutide but Americans cannot?

Patent protection is national. News reports say Novo Nordisk's Canadian semaglutide patent lapsed and its data protection ended in January 2026, so Health Canada could approve generics starting April 28, 2026. The US compound patent runs to December 5, 2031, per the FDA Orange Book.

Can I legally import generic semaglutide from Canada or India?

A Canadian or Indian generic is not FDA-approved for sale in the US. The FDA advises buying GLP-1 drugs only from state-licensed pharmacies and warns that illegally marketed versions may be counterfeit. Talk to your prescriber before you order any medicine from abroad.

Will a generic Ozempic also replace Wegovy?

Not automatically. Ozempic and Wegovy are separate FDA approvals with different doses, pens, and indications. A generic company needs an approval that references the specific brand, and the FDA Orange Book lists Wegovy patents that run as late as 2041.

How much cheaper will generic semaglutide be?

Nobody knows the US price yet. The FDA says one generic competitor is linked to price cuts of about 30%, and five competitors to drops of nearly 85%. Health Canada says generics there typically cost 45 to 90% less than the brand.

When Will Generic Semaglutide Be Available in the US?

The short answer: Not soon. The FDA Orange Book lists the core semaglutide compound patent for Ozempic, Wegovy, and Rybelsus as expiring on December 5, 2031, and Novo Nordisk tells investors US compound patent expiry is 2032. Novo has settled with at least seven generic makers, but the launch dates in those deals are confidential. Canada, India, and Brazil already have generic semaglutide in 2026, and none of those products can be legally sold in the US.

When does the US semaglutide patent expire?

The FDA's Orange Book is the official list of patents that protect a brand drug from generic copies. The Orange Book entry for Ozempic lists patent 8,129,343, which covers the semaglutide molecule itself. Its listed expiration date is December 5, 2031. The same patent appears on the Orange Book entry for Wegovy and on the entry for Rybelsus, the pill.

Novo Nordisk's own 2025 annual report on Form 20-F puts it this way: "Compound patent expiry in the US for the semaglutide branded products, Ozempic, Rybelsus, and Wegovy, is 2032." The gap between the two dates is small. The company did not explain it in that filing.

The compound patent is not the only wall. The Orange Book lists many later patents on the pens, formulations, and uses:

Ozempic: listed patents run to June 21, 2033.
Wegovy: listed patents run to February 17, 2041, most of them on the drug product.
Rybelsus: listed patents run to May 2, 2034.

Later patents can be challenged, and a generic maker can design around a pen patent. So the practical question is not the last patent date. It is what Novo agreed to in its settlements.

Have generic makers challenged the patents?

Yes. A generic company files an Abbreviated New Drug Application (ANDA) with the FDA. If it claims a listed patent is invalid or not infringed, that is a "Paragraph IV" certification, and the brand company usually sues.

Novo's 20-F says it received ANDA notices with Paragraph IV certifications for Ozempic, Wegovy, and Rybelsus. It sued. It then settled the Ozempic cases with Alvogen, Rio Biopharmaceuticals, Sun Pharma, Dr. Reddy's, Mylan, Zydus, and Apotex. The filing states: "All terms of the agreements are confidential." The agreements are subject to review by the Federal Trade Commission and the Department of Justice.

Mylan also challenged a patent on the 1 mg diabetes dose at the Patent Trial and Appeal Board in March 2023. Sun, Dr. Reddy's, and Apotex joined. Novo settled with all four in October 2024, before the hearing.

The fight is still active in 2026. In its second-quarter 2026 report, filed August 4, 2026, Novo disclosed that Cipla filed an ANDA for generic Ozempic with a Paragraph IV certification. Novo sued Cipla in federal court in New Jersey.

Because the settlement dates are secret, any specific US launch date you read online is a forecast. Treat it that way until a generic maker or the FDA announces an approval.

Is compounded or "research" semaglutide a generic?

No. The FDA explains that a generic medicine is FDA-approved and has the same active ingredient, strength, dosage form, and route as the brand. It must meet the same manufacturing standards.

Compounded semaglutide is different. The FDA states that "compounded drugs are not FDA approved" and are not reviewed for safety, effectiveness, or quality before sale. The FDA declared the semaglutide shortage resolved on February 21, 2025. The grace period for mass compounding ended on April 22, 2025 for state-licensed pharmacies and on May 22, 2025 for outsourcing facilities. Our guide to whether compounded GLP-1 drugs are safe and legal covers the details.

Products sold "for research purposes" or "not for human consumption" are not generics either. The FDA's page on unapproved GLP-1 drugs says it has acted against companies that illegally sold such products. It also warns that semaglutide salt forms may not act like the approved drug.

Where is generic semaglutide already sold?

Several large markets lost semaglutide protection in 2026. Here is where things stand as of September 21, 2026:

Canada: News reports say Novo's Canadian patent lapsed after it did not pay a maintenance fee, and its data protection ended in January 2026. On April 28, 2026, Health Canada approved Dr. Reddy's generic for type 2 diabetes, the first in the G7. Apotex followed on May 1. On June 29, Health Canada approved Sevmia, the first generic for weight management. Sandoz announced its approval on September 18, 2026.
India: The core patent expired on March 20, 2026. Dr. Reddy's launched Obeda on March 21, 2026, at INR 4,200 per month.
Brazil: The patent expired in March 2026. Reuters reported on May 26, 2026, that regulator Anvisa approved EMS's Ozivy, the first local semaglutide pen.
China: The compound patent expired on March 20, 2026, according to the South China Morning Post. China's Supreme People's Court had upheld the patent in December 2025, per Novo's 20-F. We could not confirm any generic approval in China as of this update.

Novo's Q2 2026 report confirms the effect: "In Canada, the loss of exclusivity for semaglutide has led to lower realised prices." None of these products is FDA-approved, so none can be legally marketed in the US.

Does generic liraglutide hint at what comes next?

It is the best US preview we have. Liraglutide (Victoza, Saxenda) is Novo's older daily GLP-1. Its US compound patent expired in 2023, according to Novo's 20-F.

The timeline ran like this:

Settlements licensed generic Victoza as of June 22, 2024, and Teva launched an authorized generic that month.
On December 23, 2024, the FDA approved the first generic liraglutide, from Hikma, referencing Victoza. Hikma launched it on December 26, 2024.
On August 28, 2025, Teva announced approval and launch of generic Saxenda, the first generic GLP-1 for weight loss.

Two lessons carry over. First, generic entry followed settlement dates, not a court win. Second, the diabetes version came first and the weight-loss version came more than a year later. If semaglutide follows the same path, a generic Ozempic could reach the US before a generic Wegovy. That is a pattern, not a promise.

What can you do until then?

For now, lower-cost access depends on insurance, manufacturer programs, and self-pay prices. Our guide to GLP-1 cost and insurance walks through those options. For brand-specific news on Ozempic and Wegovy, ozempic.md tracks the semaglutide products.

If you are shopping online, check that the pharmacy is state-licensed and that the product is FDA-approved. A price that looks like a Canadian or Indian generic, sold to a US address, is a warning sign.

The bottom line

The earliest public date for US generic semaglutide is the compound patent's December 5, 2031 expiry, and Novo says 2032. Settlements with at least seven generic makers may set the real date, but those terms are confidential. Canada, India, and Brazil show generics can arrive fast once protection ends. Until the FDA approves one, no generic semaglutide is legally sold in the US.

Last updated: September 2026. This article is for informational purposes only and does not constitute medical or legal advice. Patent and approval dates change often, so check with your prescriber or pharmacist before making decisions about your medication.